Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: A retrospective study

R. Ramanathan, J. J. Bhatia, K. Sekar, F. R. Ernst

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective:The objective of this study is to compare all-cause in-hospital mortality in preterm infants with respiratory distress syndrome (RDS) treated with poractant alfa, calfactant or beractant.Study Design:A retrospective cohort study of 14 173 preterm infants with RDS, treated with one of three surfactants between 2005 and 2009, using the Premier Database was done. Multilevel, multivariable logistic regression modeling, adjusting for patient- and hospital-level factors was performed.Result:Calfactant treatment was associated with a 49.6% greater likelihood of death than poractant alfa (odds ratio (OR): 1.496, 95% confidence interval (CI): 1.014-2.209, P=0.043). Beractant treatment was associated with a non-significant 37% increase in mortality, compared with poractant alfa (OR: 1.370, 95% CI: 0.996-1.885, P=0.053). No differences in mortality were observed between calfactant and beractant treatment (OR: 1.092, 95% CI: 0.765-1.559, P=0.626).Conclusion:Poractant alfa treatment for RDS was associated with a significantly reduced likelihood of death when compared with calfactant and a trend toward reduced mortality when compared with beractant.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalJournal of Perinatology
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Newborn Respiratory Distress Syndrome
Premature Infants
Retrospective Studies
Mortality
Odds Ratio
Confidence Intervals
Therapeutics
Hospital Mortality
Surface-Active Agents
Cohort Studies
Logistic Models
Databases
poractant alfa
calfactant
beractant

Keywords

  • beractant
  • calfactant
  • mortality
  • poractant alfa
  • respiratory distress syndrome
  • surfactant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant : A retrospective study. / Ramanathan, R.; Bhatia, J. J.; Sekar, K.; Ernst, F. R.

In: Journal of Perinatology, Vol. 33, No. 2, 01.02.2013, p. 119-125.

Research output: Contribution to journalArticle

@article{16884ecaa24c45b0b96bd98a31dfd505,
title = "Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: A retrospective study",
abstract = "Objective:The objective of this study is to compare all-cause in-hospital mortality in preterm infants with respiratory distress syndrome (RDS) treated with poractant alfa, calfactant or beractant.Study Design:A retrospective cohort study of 14 173 preterm infants with RDS, treated with one of three surfactants between 2005 and 2009, using the Premier Database was done. Multilevel, multivariable logistic regression modeling, adjusting for patient- and hospital-level factors was performed.Result:Calfactant treatment was associated with a 49.6{\%} greater likelihood of death than poractant alfa (odds ratio (OR): 1.496, 95{\%} confidence interval (CI): 1.014-2.209, P=0.043). Beractant treatment was associated with a non-significant 37{\%} increase in mortality, compared with poractant alfa (OR: 1.370, 95{\%} CI: 0.996-1.885, P=0.053). No differences in mortality were observed between calfactant and beractant treatment (OR: 1.092, 95{\%} CI: 0.765-1.559, P=0.626).Conclusion:Poractant alfa treatment for RDS was associated with a significantly reduced likelihood of death when compared with calfactant and a trend toward reduced mortality when compared with beractant.",
keywords = "beractant, calfactant, mortality, poractant alfa, respiratory distress syndrome, surfactant",
author = "R. Ramanathan and Bhatia, {J. J.} and K. Sekar and Ernst, {F. R.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1038/jp.2011.125",
language = "English (US)",
volume = "33",
pages = "119--125",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant

T2 - A retrospective study

AU - Ramanathan, R.

AU - Bhatia, J. J.

AU - Sekar, K.

AU - Ernst, F. R.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Objective:The objective of this study is to compare all-cause in-hospital mortality in preterm infants with respiratory distress syndrome (RDS) treated with poractant alfa, calfactant or beractant.Study Design:A retrospective cohort study of 14 173 preterm infants with RDS, treated with one of three surfactants between 2005 and 2009, using the Premier Database was done. Multilevel, multivariable logistic regression modeling, adjusting for patient- and hospital-level factors was performed.Result:Calfactant treatment was associated with a 49.6% greater likelihood of death than poractant alfa (odds ratio (OR): 1.496, 95% confidence interval (CI): 1.014-2.209, P=0.043). Beractant treatment was associated with a non-significant 37% increase in mortality, compared with poractant alfa (OR: 1.370, 95% CI: 0.996-1.885, P=0.053). No differences in mortality were observed between calfactant and beractant treatment (OR: 1.092, 95% CI: 0.765-1.559, P=0.626).Conclusion:Poractant alfa treatment for RDS was associated with a significantly reduced likelihood of death when compared with calfactant and a trend toward reduced mortality when compared with beractant.

AB - Objective:The objective of this study is to compare all-cause in-hospital mortality in preterm infants with respiratory distress syndrome (RDS) treated with poractant alfa, calfactant or beractant.Study Design:A retrospective cohort study of 14 173 preterm infants with RDS, treated with one of three surfactants between 2005 and 2009, using the Premier Database was done. Multilevel, multivariable logistic regression modeling, adjusting for patient- and hospital-level factors was performed.Result:Calfactant treatment was associated with a 49.6% greater likelihood of death than poractant alfa (odds ratio (OR): 1.496, 95% confidence interval (CI): 1.014-2.209, P=0.043). Beractant treatment was associated with a non-significant 37% increase in mortality, compared with poractant alfa (OR: 1.370, 95% CI: 0.996-1.885, P=0.053). No differences in mortality were observed between calfactant and beractant treatment (OR: 1.092, 95% CI: 0.765-1.559, P=0.626).Conclusion:Poractant alfa treatment for RDS was associated with a significantly reduced likelihood of death when compared with calfactant and a trend toward reduced mortality when compared with beractant.

KW - beractant

KW - calfactant

KW - mortality

KW - poractant alfa

KW - respiratory distress syndrome

KW - surfactant

UR - http://www.scopus.com/inward/record.url?scp=84873184391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873184391&partnerID=8YFLogxK

U2 - 10.1038/jp.2011.125

DO - 10.1038/jp.2011.125

M3 - Article

C2 - 21886094

AN - SCOPUS:84873184391

VL - 33

SP - 119

EP - 125

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 2

ER -